Eon Sporanox Generic Cleared To Launch By Court
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is reviewing a trial court’s ruling that it does not infringe a Janssen patent before deciding whether to launch. Eon says its 180-day exclusivity will not be triggered until commercial marketing or an appellate court decision.
You may also be interested in...
Sporanox Generic Launches
Eon launched the first generic of Janssen's antifungal Sporanox (itraconazole), the company announced Feb. 9
Sporanox Generic Launches
Eon launched the first generic of Janssen's antifungal Sporanox (itraconazole), the company announced Feb. 9
Eon Generic Sporanox Approved; Launch Will Await Ruling In Litigation With Janssen
Eon’s ANDA for itraconazole is approved with 180-day marketing exclusivity, but launch depends on the outcome of the patent case. A judge’s decision on infringement and the doctrine of equivalents is pending.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: